|
Total no. of patients
|
24
|
4
|
|
Checkpoint inhibitor type
|
|
CTLA-4
|
6 (25)
|
2 (50)
|
|
PD-1/L1
|
11 (46)
|
1 (25)
|
|
Combination
|
7 (29)
|
1 (25)
|
|
Mean duration of steroid therapy, days(SD)
|
95 (79)
|
99 (52)
|
|
Median time from symptom onset to vedolizumab/infliximab therapy, days (IQR)
|
19 (6–152)
|
9 (4–67)
|
|
Median no. of vedolizumab doses (IQR)
|
3 (1–4)
|
3 (1–4)
|
|
Mean fecal calprotectin level at time of onset μg/g (SD)
|
299 (236)
|
586 (584)
|
|
Peak grade of diarrhea
|
|
2
|
12 (50)
|
2 (50)
|
|
3–4
|
12 (50)
|
2 (50)
|
|
Initial endoscopic findings
|
|
Ulceration
|
6 (25)
|
3 (75)
|
|
Nonulcerative inflammation
|
12 (50)
|
0 (0)
|
|
Normal
|
6 (25)
|
1 (25)
|
|
Initial histologic findings
|
|
Active features
|
24 (100)
|
4 (100)
|
|
Chronic features
|
10 (42)
|
4 (100)
|
|
Microscopic
|
9 (38)
|
1 (25)
|
|
Mean overall duration of disease months (SD)
|
5 (3)
|
8 (5)
|
|
Mean fecal calprotectin level after vedolizumab therapy μg/g (SD)
|
187 (108)
|
270 (487)
|
|
Last repeat endoscopic findingsa
|
|
Ulceration
|
1 (8)
|
3 (75)
|
|
Nonulcerative inflammation
|
6 (46)
|
0 (0)
|
|
Normal
|
6 (46)
|
1 (25)
|
|
Active features on last repeat histologic analysisa
|
9 (69)
|
4 (100)
|
